$-0.10
(Market cap
$881 Mln
Revenue (TTM)
$97 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-17.3
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$-2.3
-
Face value
--
-
Shares outstanding
74,141,596
10 Years Aggregate
CFO
$138.61 Mln
EBITDA
$-344.02 Mln
Net Profit
$-265.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xencor (XNCR)
| -22.2 | -10.9 | -6.5 | 30.9 | -24.5 | -20.0 | -1.9 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Xencor (XNCR)
| -33.4 | 8.2 | -18.5 | -35.1 | -8.0 | 26.9 | -4.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xencor (XNCR)
|
11.9 | 880.8 | 97.4 | -172.4 | -98.6 | -30.2 | -- | 1.7 |
| 73.2 | 10,974.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.1 | |
| 212.8 | 13,845.5 | 867.5 | 506.6 | -2.8 | -- | 25.5 | 25.6 | |
| 71.1 | 10,421.8 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 52.6 | 12,688.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.7 | 6.5 | |
| 308.9 | 9,110.1 | 417.3 | 225.0 | 42.8 | 18.6 | 41.4 | 7.1 | |
| 490.0 | 11,464.9 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.4 | |
| 455.6 | 12,769.3 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.2 | 20.4 | |
| 91.3 | 8,720.6 | 0.0 | -450.1 | -- | -44.6 | -- | 7.2 | |
| 258.8 | 9,756.7 | 0.0 | -326.5 | -- | -37.2 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Xencor (XNCR)
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic... uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California. Read more
-
Co-Founder, CEO, President & Director
Dr. Bassil I. Dahiyat Ph.D.
-
Co-Founder, CEO, President & Director
Dr. Bassil I. Dahiyat Ph.D.
-
Headquarters
Pasadena, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Xencor (XNCR)
What is the current share price of Xencor Inc (XNCR) Today?
The share price of Xencor Inc (XNCR) is $11.91 (NASDAQ) as of 05-Jun-2026 13:41 EDT. Xencor Inc (XNCR) has given a return of -24.51% in the last 3 years.
What is the current PB & PE ratio of Xencor Inc (XNCR)?
Since, TTM earnings of Xencor Inc (XNCR) is negative, P/E ratio is not available.
The P/B ratio of Xencor Inc (XNCR) is 1.67 times as on 29-May-2026, a 62 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-12.36
|
1.79
|
|
2024
|
-7.23
|
2.48
|
|
2023
|
-10.25
|
1.93
|
|
2022
|
-28.27
|
2.14
|
|
2021
|
29.30
|
3.30
|
What is the 52 Week High and Low of Xencor Inc (XNCR)?
The 52-week high and low of Xencor Inc (XNCR) are Rs 18.69 and Rs 6.92 as of 07-Jun-2026.
What is the market cap of Xencor Inc (XNCR)?
Xencor Inc (XNCR) has a market capitalisation of $ 881 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Xencor Inc (XNCR)?
Before investing in Xencor Inc (XNCR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.